Hydrogel-based formulations for urothelial cancer therapy

Area of Science:

• Biomaterials Science
• Oncology
• Urology

Background:

• Drug infusion therapy is crucial for reducing urothelial carcinoma recurrence post-surgery.
• Hydrogels offer biocompatible drug delivery with high loading capacity, optimizing urinary system pharmacokinetics.
• Traditional free drug perfusion faces challenges with urinary flushing, limiting efficacy.

Purpose of the Study:

• To review the research progress of hydrogels in treating urothelial carcinoma.
• To highlight the advantages of hydrogel drug loading systems over traditional methods.
• To provide a reference for developing advanced hydrogels for urothelial cancer treatment.

Main Methods:

• Hydrogel drug carriers with good mucosal adhesion improve drug retention time.
• Combination of hydrogels with nanoparticles and magnetic materials enhances mucosal permeability and targeting.
• Exploration of various therapeutic strategies including chemotherapy, immunotherapy, and gene therapy within hydrogels.

Main Results:

• Hydrogel systems maintain effective drug concentrations despite urinary flushing.
• Prolonged drug retention improves therapeutic effects and reduces patient discomfort and infection risk.
• Enhanced targeting minimizes impact on normal tissues and overcomes physiological barriers.

Conclusions:

• Hydrogels represent a promising advanced drug delivery system for urothelial carcinoma treatment.
• Hydrogel-based therapies offer improved efficacy, safety, and patient compliance.
• Further research into hydrogel applications can lead to more effective and less invasive urothelial cancer treatments.